<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sleep-related breathing disorders in COPD
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sleep-related breathing disorders in COPD
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sleep-related breathing disorders in COPD
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Safwan Badr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Umur Hatipoglu, MD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H10592032">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic obstructive pulmonary disease (COPD) is frequently associated with sleep-related breathing disorders (SRBD), including sleep-related hypoxemia, obstructive sleep apnea, central sleep apnea, respiratory effort-related arousals (RERAs), and sleep-related hypoventilation. These SRBDs may be associated with nonrestorative sleep and daytime sleepiness and fatigue [
         <a href="#rid1">
          1-10
         </a>
         ].
        </p>
        <p>
         The various forms of SRBD in COPD will be reviewed here, with special emphasis on (1) the diagnostic procedures required to detect the COPD-specific SRBD and (2) specific treatment options for SRBD in patients with COPD. A description of SRBD and the evaluation, diagnosis, and treatment of COPD and obstructive and central sleep apnea occurring independently are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10592038">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep-related breathing disorders (SRBD) are common in patients with COPD [
         <a href="#rid1">
          1
         </a>
         ], occurring in approximately 30 to 40 percent of patients [
         <a href="#rid11">
          11-13
         </a>
         ].
        </p>
        <p>
         There are four major domains of sleep-disordered breathing in COPD patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related hypoxemia
         </strong>
         – The prevalence of sleep-related hypoxemia (also called nocturnal hypoxemia) increases along with the severity of COPD [
         <a href="#rid2">
          2
         </a>
         ]. Sleep-related hypoxemia is often associated with daytime hypoxemia, but not always. Isolated sleep-related hypoxemia (fall in partial pressure of arterial oxygen [PaO
         <sub>
          2
         </sub>
         ] of &gt;10 mmHg or pulse oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] below 88 percent for more than five minutes) has been reported in up to 70 percent of COPD patients, and can occur in patients with daytime oxygen saturation of 90 to 95 percent [
         <a href="#rid3">
          3,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coexisting obstructive sleep apnea
         </strong>
         – Moderate to severe obstructive sleep apnea (OSA) may be present in 10 to 30 percent of patients with COPD, a prevalence that is similar to that of the general population [
         <a href="#rid1">
          1-3,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The coexistence of OSA and COPD has been referred to as the "overlap syndrome" [
         <a href="#rid16">
          16
         </a>
         ], although it is unclear whether it is truly an overlap syndrome or just two common diseases presenting together.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoventilation during sleep
         </strong>
         – Sleep-related hypoventilation is defined as a greater than normal increase in arterial tension of carbon dioxide (PaCO
         <sub>
          2
         </sub>
         ) during sleep (PaCO
         <sub>
          2
         </sub>
         of &gt;50 mmHg or rise in PaCO
         <sub>
          2
         </sub>
         of &gt;10 mmHg for more than 10 minutes compared to wakefulness). The prevalence of sleep-related hypoventilation is approximately 43 percent in hypercapnic patients with COPD but is lower (approximately 6 to 10 percent) and often limited to rapid eye movement (REM) sleep in patients with mild COPD and normal daytime arterial blood gases [
         <a href="#rid1">
          1,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory effort related arousals
         </strong>
         – Respiratory effort related arousals [RERAs], also described as sleep fragmentation due to worsening of breathing mechanics, can be seen in COPD (see
         <a class="local">
          'Pathophysiology'
         </a>
         below). The prevalence, however, remains unclear [
         <a href="#rid1">
          1,18,19
         </a>
         ], and the clinical significance may be limited to patients with advanced stages of COPD with greater degrees of hyperinflation and muscle weakness [
         <a href="#rid20">
          20
         </a>
         ]. RERAs are accounted for in summary measures of OSA severity and are generally considered to be on the pathophysiologic spectrum of OSA. However, COPD-specific alterations in breathing due to lower airway abnormalities may also contribute to RERAs in patients with COPD. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Respiratory effort-related arousals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – A meta-analysis of 60 studies in patients with COPD and sleep disorders reported a prevalence of 22 percent for restless leg syndrome and 29 percent for insomnia [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10592068">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the exact pathogenesis of nocturnal hypoxemia in COPD is unclear, normal sleep-related decline in ventilatory motor output exacerbates ventilation-perfusion mismatch and hypoventilation in individuals with COPD and can cause a marked deterioration in gas transfer, particularly during rapid eye movement (REM) sleep [
         <a href="#rid17">
          17,21,22
         </a>
         ]. In addition, COPD can lead to elevations in closing volume, which means that the small airways in the lung are closed during tidal volume breathing and not participating fully in gas exchange. The increase in closing volume in combination with a reduction in functional residual capacity during sleep can exacerbate ventilation-perfusion mismatch and hypoxemia [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Sleep is associated with decreased hypoxic and hypercapnic ventilatory responses [
         <a href="#rid24">
          24
         </a>
         ]. This sleep-related ventilatory depression leads to modest elevations in arterial tension of carbon dioxide (PaCO
         <sub>
          2
         </sub>
         ) in normal individuals compared with awake values [
         <a href="#rid24">
          24
         </a>
         ]. In addition, sleep is associated with a loss of drive to upper airway dilator muscles [
         <a href="#rid25">
          25,26
         </a>
         ], leading to upper airway narrowing and subsequent inspiratory airflow limitation in normal non-snoring and snoring individuals without sleep apnea [
         <a href="#rid27">
          27
         </a>
         ]. Reductions in inspiratory airflow can further compromise ventilation and increase PaCO
         <sub>
          2
         </sub>
         . (See
         <a class="medical medical_review" href="/z/d/html/7712.html" rel="external">
          "Pathophysiology of upper airway obstruction in obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
         COPD is associated with alterations in respiratory mechanics and gas exchange that can lead to dynamic hyperinflation and/or hypoventilation [
         <a href="#rid28">
          28
         </a>
         ]. During wakefulness, patients adopt specific mechanisms to minimize hyperinflation (by prolonging expiratory time) and to preserve alveolar ventilation (with pursed lip breathing) [
         <a href="#rid29">
          29-31
         </a>
         ]. Sleep is associated with several changes in respiratory control that interfere with the compensatory mechanisms used during wakefulness. In COPD, reductions in ventilation during sleep can produce marked elevations in PaCO
         <sub>
          2
         </sub>
         because of concomitant elevations in dead space ventilation [
         <a href="#rid32">
          32
         </a>
         ]. Mechanisms to minimize hypoventilation will exacerbate dynamic hyperinflation, whereas lengthening expiratory time could compromise ventilation during sleep.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A loss of ventilatory drive leads to significant reductions in tidal volume [
         <a href="#rid33">
          33
         </a>
         ], and compensatory mechanisms to prevent hypoventilation are left to changes in respiratory pattern. An increase in inspiratory time would increase tidal volume but would reduce expiratory time, potentially exacerbating air trapping. Similarly, an increase in respiratory rate would maintain minute ventilation but also reduce expiratory time. In either case, respiratory patterns during sleep in COPD can worsen dynamic hyperinflation by shortening expiratory time [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inspiratory flow limitation (IFL) is commonly observed during sleep and even mild degrees of IFL lengthen inspiratory time, further comprising expiratory time [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Thus, sleep induces specific alterations in breathing pattern that compromise ventilation and increase ventilatory loads in COPD. It has been shown that hyperinflation is associated with reductions in sleep efficiency [
         <a href="#rid20">
          20
         </a>
         ]. Moreover, the mechanism by which these changes contribute to sleep fragmentation and morning fatigue in COPD is likely due to increased arousal frequency (RERAs) and is under clinical investigation [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Obstructive sleep apnea (OSA) is characterized by increased collapsibility of the upper airway leading to inspiratory flow limitation, manifest by snoring, hypopneas, and apneas. The interrelationship of COPD and OSA is complicated, as the manifestations of COPD can vary among individual patients. As an example, some patients have a more emphysematous presentation and others have more airways disease (chronic bronchitis) with less air trapping. Increasing lung volumes due to air trapping are associated with improvements in upper airway collapsibility [
         <a href="#rid34">
          34
         </a>
         ], which may explain why COPD patients with emphysema (pink puffer) typically do not present with concomitant OSA while obese COPD patients (blue bloater) exhibit significant OSA more often. Regardless, the coexistence of OSA and COPD has been associated with more pronounced hypoxemia and hypercapnia compared with COPD or OSA individually.
        </p>
        <p class="headingAnchor" id="H10592074">
         <span class="h1">
          CONTRIBUTING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with COPD have multiple comorbid conditions that are associated with an increased risk of sleep-related breathing disorders, such as metabolic syndrome (approximately 25 to 50 percent), smoking, cardiovascular diseases, and opioid use [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H551816089">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of obesity (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ) in COPD is increasing, ranging from 25 to 42 percent [
         <a href="#rid38">
          38
         </a>
         ]. In patients with COPD and obesity, respiratory disturbances and blood gas abnormalities (hypoxemia and hypercapnia) first occur during sleep, when ventilation responsiveness to chemical stimuli is blunted and the wakefulness drive is reduced. In addition, decreases in accessory muscle activity, particularly during rapid eye movement (REM) sleep, place an additional burden on the diaphragm, which is already under mechanical disadvantage.
        </p>
        <p>
         Moreover, obesity is the strongest predictor for having coexisting obstructive sleep apnea (OSA). A BMI &gt;30 kg/m
         <sup>
          2
         </sup>
         increases the probability of having OSA to more than 50 percent in males and approximately 20 to 30 percent in females.
        </p>
        <p>
         In patients with COPD and obesity, positive airway pressure may not only mitigate OSA but also offset the mechanical disadvantage in obese COPD patients [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H767738343">
         <span class="h2">
          Smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Current smokers have a greater likelihood of snoring and SRBD relative to never smokers [
         <a href="#rid39">
          39
         </a>
         ]. Inhalation of nicotine in cigarette smoke and withdrawal from nicotine during smoking cessation can also cause sleep disruption [
         <a href="#rid40">
          40,41
         </a>
         ]. Conversely, oxyhemoglobin desaturation may be obscured by the presence of carboxyhemoglobin, which shifts the oxyhemoglobin dissociation curve to the left [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H924467362">
         <span class="h2">
          Heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central sleep apnea is not commonly seen in patients with COPD but can develop in the presence of heart failure or other cardiovascular comorbidities. The primary predisposing condition for central sleep apnea is heart failure with a reduction in cardiac output, leading to Cheyne Stokes type of central apnea. The presence of heart failure with reduced ejection fraction (below 40 percent) increases likelihood of having central sleep apnea to more than 50 percent. (See
         <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">
          "Sleep-disordered breathing in heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2527825127">
         <span class="h2">
          Opioid use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic opioid use is an increasingly recognized risk factor for SRBD. Central sleep apnea is the most common form, although obstructive and mixed patterns also occur. Central sleep apnea related to opioid use is often marked by irregular respiratory patterns, including ataxic breathing. (See
         <a class="medical medical_review" href="/z/d/html/97859.html" rel="external">
          "Sleep-disordered breathing in patients chronically using opioids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H647090835">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The symptoms and signs of SRBD in patients with COPD are essentially the same as for patients without COPD  (
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 1
         </a>
         ). However, patients may be asymptomatic or their symptoms may overlap with the features of COPD itself and are thus not reported.
        </p>
        <p>
         A large study demonstrated that nighttime symptoms in COPD patients frequently go unnoticed by physicians and may not be reported by patients themselves [
         <a href="#rid6">
          6,43,44
         </a>
         ]. Thus, a specific sleep history should be sought from both the patient and the bed partner because, in many cases, it is only the bed partner who is aware of the abnormal ventilatory pattern.
        </p>
        <p>
         The symptoms and signs of SRBD in patients with COPD include snoring, insomnia, awakening with a sensation of gasping or choking, morning headaches, daytime sleepiness or fatigue, and poor concentration or memory impairment  (
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 1
         </a>
         ). Additional features that may suggest SRBD include a large neck circumference, shallow or "crowded airway," and obesity.
        </p>
        <p>
         Patients with severe COPD typically have disrupted sleep and often have desaturations during non-rapid eye movement (NREM) sleep that are more pronounced during rapid eye movement (REM) sleep [
         <a href="#rid45">
          45
         </a>
         ]. In a population-based study, nocturnal oxygen desaturation was more common among those whose forced expiratory volume in one second/forced vital capacity (FEV
         <sub>
          1
         </sub>
         /FVC) ratio was &lt;0.65 [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         While patients with acute hypercapnia may develop symptoms of hypercapnia (eg, anxiety, dyspnea, daytime sluggishness, morning headaches, hypersomnolence, confusion) when the arterial tension of carbon dioxide (PaCO
         <sub>
          2
         </sub>
         ) is above 75 mmHg, patients with chronic hypercapnia may not develop symptoms until the PaCO
         <sub>
          2
         </sub>
         rises above 90 mmHg. (See
         <a class="medical medical_review" href="/z/d/html/101436.html" rel="external">
          "Mechanisms, causes, and effects of hypercapnia", section on 'Effects of hypercapnia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10592105">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of SRBD in patients with COPD requires a high index of suspicion and formal sleep testing with polysomnography, since clinical features and questionnaires lack sensitivity and often overlap with symptoms of COPD.
        </p>
        <p>
         Detecting SRBD is challenging in patients with COPD due to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary sleep problems reported by patients are difficulties initiating and maintaining sleep and reduced sleep time, and these often supersede other symptoms of SRBD such as unrefreshed sleep, waking up gasping and choking, morning headaches, and increased daytime sleepiness [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nocturnal hypoxemia, while commonly observed in COPD patients with borderline daytime oxygen levels of 90 to 95 percent, does not produce specific symptoms [
         <a href="#rid3">
          3
         </a>
         ] and often remains undetected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standardized questionnaires for screening and determining probability of obstructive sleep apnea (OSA), such as the Epworth Sleepiness Scale and the Sleep Apnea Clinical Score, have limited utility and are not validated for use in COPD patients [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1785384002">
         <span class="h2">
          When should SRBD be suspected in COPD?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following criteria have been recommended as indications for evaluation for possible sleep-related breathing disorders in COPD [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with COPD who report typical symptoms suggestive of OSA such as snoring (especially expiratory), gasping and choking, morning headaches, or increased daytime sleepiness [
         <a href="#rid48">
          48
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity (body mass index [BMI] &gt;30 in males, 40 in females) with or without specific symptoms of OSA
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced daytime pulse oxygen saturation (below 93 percent) at rest or during exercise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daytime hypercapnia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neck circumference &gt;43 cm (17 inches) in males and &gt;41 cm (16 inches) in females
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs of pulmonary hypertension or right heart failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polycythemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morning headaches, especially in response to oxygen therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who use drugs that are known to affect breathing such as opioids and hypnotic medications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbidities known to be associated with OSA (eg, atrial fibrillation, diabetes type 2, end-stage kidney disease, heart failure, stroke, systemic arterial hypertension)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1454597841">
         <span class="h2">
          Overnight pulse oximetry
         </span>
         <span class="headingEndMark">
          —
         </span>
         For asymptomatic patients with a resting awake pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) of 90 to 95 percent, overnight oximetry at home may be an appropriate initial step as a screening device for transient or sustained nocturnal hypoxemia and certain types of SRBD [
         <a href="#rid3">
          3,49,50
         </a>
         ].
        </p>
        <p>
         Among patients with sleep-related desaturation detected by overnight oximetry, approximately half have OSA, and an in-laboratory polysomnogram (PSG) or home sleep apnea test (HSAT) is needed to identify these patients  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ). However, overnight oximetry when measured alone is not recommended as a screening test for OSA. (See
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults", section on 'Pulse oximetry'
         </a>
         .)
        </p>
        <p>
         The reliability of overnight pulse oximetry in COPD was found to be consistent in identifying nocturnal hypoxemia in one study [
         <a href="#rid50">
          50
         </a>
         ] that found transient or sustained hypoxemia without evidence of sleep apnea in a significant proportion (38 percent) of patients with moderate to severe COPD (mean forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] 37 percent) who did not qualify for home oxygen therapy based on their daytime partial pressure of arterial oxygen (PaO
         <sub>
          2
         </sub>
         ) of 56 to 69 mmHg [
         <a href="#rid50">
          50
         </a>
         ]. In contrast, another study found that significant variability between two overnight oximetry studies, such that 35 percent of patients had a different result on the second night [
         <a href="#rid51">
          51
         </a>
         ]. Thus, more than one night of observation may be appropriate to adequately evaluate nocturnal hypoxemia.
        </p>
        <p class="headingAnchor" id="H2579776910">
         <span class="h2">
          Home sleep apnea test
         </span>
         <span class="headingEndMark">
          —
         </span>
         HSAT is widely used for the diagnosis of OSA in otherwise healthy individuals and has the potential advantage of more rapid implementation of treatment with positive airway pressure. Improvements in HSAT technology, including devices that monitor sleep stages, respiratory abnormalities during sleep, and oximetry, and supervision of HSAT by a board-certified sleep physician have led to greater acceptability of HSAT in patients with mild-to-moderate COPD and suspected OSA  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid52">
          52
         </a>
         ]. Patient selection, features of acceptable devices, and use of HSAT for the diagnosis of OSA are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
         The 2017 guidelines of the American Academy of Sleep Medicine recommend a step-wise approach that includes in-lab studies when a single overnight screening has not detected (ruled in) either significant sleep apnea or nocturnal hypoxemia. Rather than repeating HSAT, they recommend moving one step up to a full polysomnography study in the sleep lab [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         One difficulty is determining the severity of COPD that would make HSAT inappropriate, and the American Academy of Sleep Medicine Guidelines (AASM) do not provide a specific threshold re COPD severity. One study of 72 patients with stable COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 or 3 and symptoms of OSA found a high rate of recording failures with HSAT and variable correlation with in-laboratory PSG [
         <a href="#rid53">
          53
         </a>
         ]. These results suggest that HSAT is less likely to be helpful in patients with COPD GOLD stage 2 or higher. In addition, HSAT does not include sufficient monitoring to detect the full range of COPD-specific SRBD, such as hypoventilation without severe hypoxemia (requires CO
         <sub>
          2
         </sub>
         monitoring devices) or periods of inspiratory and expiratory airflow limitation leading to frequent arousal [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         If HSAT is nondiagnostic, guidelines suggest an in-laboratory PSG, rather than a repeat HSAT. In-laboratory PSG is still preferred over HSAT for patients with moderate-to-severe cardiorespiratory disease [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2440161438">
         <span class="h2">
          In-laboratory polysomnography
         </span>
         <span class="headingEndMark">
          —
         </span>
         In-laboratory PSG is the gold standard for the diagnosis of SRBD and is able to detect the full range of COPD-specific SRBD, such as hypoventilation without severe hypoxemia (using CO
         <sub>
          2
         </sub>
         monitoring devices), central sleep apnea, and periods of inspiratory and expiratory airflow limitation leading to frequent arousal [
         <a href="#rid47">
          47
         </a>
         ]. An approach to choosing between HSAT and in-laboratory PSG is provided in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults"
         </a>
         .)
        </p>
        <p>
         Indications for an in-laboratory study rather than HSAT include the following [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspicion of nonrespiratory sleep disorders (eg, parasomnia, severe insomnia, sleep-related movement disorder)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid conditions that increase the likelihood of nonobstructive sleep-disordered breathing (eg, significant cardiorespiratory disease, potential respiratory muscle weakness, severe insomnia, and history of stroke or chronic opiate use). As noted above, significant COPD would generally include those with GOLD stage 2 or higher and COPD associated with hypercapnia or resting SpO
         <sub>
          2
         </sub>
         &lt;89 percent, although these thresholds have not been clearly defined. (See
         <a class="local">
          'Home sleep apnea test'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2948327918">
         <span class="h3">
          Full-night study (preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with symptoms or signs of a SRBD, the preferred test is a standard in-laboratory PSG with continuous monitoring of carbon dioxide via an end-tidal (etCO
         <sub>
          2
         </sub>
         ) or transcutaneous (tcCO
         <sub>
          2
         </sub>
         ) system, particularly in those patients with daytime hypercapnia or daytime hypoxemia.
        </p>
        <p>
         Full-night PSG is preferred over a split-night study for patients with COPD, even if severe sleep apnea is apparent in the first third of the night in a range that would qualify for continuous positive airway pressure (CPAP), because patients with COPD may have more than one type of SRBD. Patients with severe emphysema often use accessory intercostals muscles to support ventilation. These patients are more vulnerable to decompensation during rapid eye movement (REM) sleep due to muscle atonia/hypotonia, and REM sleep usually predominates in the second half of the night. A full-night PSG will allow determination of whether REM sleep-related hypotonia/atonia worsens OSA, gas transfer, and breathing mechanics. (See
         <a class="local">
          'Split-night protocol'
         </a>
         below.)
        </p>
        <p>
         Additional considerations relevant to patients with COPD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related hypercapnia
         </strong>
         – In patients with COPD, tcCO
         <sub>
          2
         </sub>
         monitoring is the preferred method to detect sleep-related hypercapnia or worsening of hypercapnia because etCO
         <sub>
          2
         </sub>
         underestimates CO
         <sub>
          2
         </sub>
         due to abnormalities in breathing mechanics and shortened expiratory time during inspiratory flow limitation. In addition, etCO
         <sub>
          2
         </sub>
         cannot be performed during titration of PAP. However, etCO
         <sub>
          2
         </sub>
         monitoring is more widely available than tcCO
         <sub>
          2
         </sub>
         monitoring. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Ventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periodic leg movements
         </strong>
         – Special emphasis should also be placed on monitoring periodic leg movements, as periodic leg movements of sleep (PLMS) are common during non-REM (NREM) sleep in COPD patients and they can be mistaken for respiratory events, when associated with either arousal or inspiratory flow limitation [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99555.html" rel="external">
          "Polysomnography in the evaluation of abnormal movements during sleep"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supplemental oxygen
         </strong>
         – In patients with daytime hypoxemia who desaturate readily during sleep, supplemental oxygen will markedly alter the frequency and severity of nocturnal oxyhemoglobin desaturations. Most COPD sleep centers initiate a sleep study omitting supplemental oxygen in patients who have pulse oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) levels &gt;88 percent and then add oxygen if SpO
         <sub>
          2
         </sub>
         decreases to below 88 percent in NREM sleep for more than 10 minutes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H203142174">
         <span class="h3">
          Split-night protocol
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a high likelihood of OSA and
         <strong>
          without
         </strong>
         baseline hypercapnia, it may be practical to order a split-night study with initial documentation of OSA and then initiation of CPAP, following the usual acceptability criteria that are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7696.html" rel="external">
          "Overview of polysomnography in adults", section on 'Split-night protocol'
         </a>
         .)
        </p>
        <p>
         Although split-night studies are now well established for sleep apnea patients, their value in COPD patients remains unclear for the following reasons: (1) REM sleep represents a particular vulnerability for patients with COPD and documentation of the REM effect often cannot be obtained from the first two to three hours of sleep; (2) Initiation of CPAP can worsen hyperinflation and may cause patients to reject CPAP in the latter part of the night. A careful adaptation to CPAP and its modalities are warranted in these cases.
        </p>
        <p class="bulletIndent1">
         A split-night study must document an apnea hypopnea index (AHI) ≥40 during a minimum of two hours and then titrate CPAP for more than three hours, as respiratory events can worsen during the latter part of the night. CPAP must eliminate respiratory events during REM and NREM sleep, including REM sleep when supine.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2701348840">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for the various forms of SRBD have been established by the AASM [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related hypoxemia
         </strong>
         – Significant sleep-related hypoxemia is defined as a SpO
         <sub>
          2
         </sub>
         of ≤88 percent (≤90 percent in children) for ≥5 minutes that is not fully explained by sleep-related hypoventilation, OSA, or other SRBD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstructive sleep apnea
         </strong>
         – OSA is defined by the presence of ≥5 predominantly obstructive respiratory events (ie, obstructive and mixed apneas, hypopneas, or respiratory effort-related arousals [RERAs]) per hour of sleep (for in-laboratory PSG) or recording time (for out-of-center sleep testing)
         <strong>
          and
         </strong>
         symptoms (eg, sleepiness, fatigue, insomnia, awakening with gasping or choking, snoring); or ≥15 predominantly obstructive respiratory events, independent of symptoms [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central sleep apnea
         </strong>
         – Central sleep apnea (CSA) is defined by the presence of ≥5 central apneas and/or hypopneas per hour of sleep (or recording time if a home study) plus a requirement that more than 50 percent of the total number of apneas and hypopneas are central [
         <a href="#rid54">
          54
         </a>
         ]. In addition, patients must have one or more symptoms related to the disorder (eg, sleepiness, insomnia, frequent awakenings, nonrestorative sleep, awakening short of breath, witnessed apneas). (See
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related hypoventilation
         </strong>
         – Sleep-related hypoventilation is defined as an arterial tension of CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) &gt;55 mmHg for ≥10 minutes or an increase in PaCO
         <sub>
          2
         </sub>
         ≥10 mmHg during sleep (compared with an awake supine value) to a value &gt;50 mmHg for ≥10 minutes [
         <a href="#rid55">
          55
         </a>
         ]. The primary cause of hypoventilation is related to COPD (or another pulmonary disorder), but not obesity hypoventilation syndrome, medication use, or a known congenital central alveolar hypoventilation syndrome [
         <a href="#rid54">
          54
         </a>
         ]. Sleep-related hypoventilation is generally most severe during REM sleep. Hypoxemia may or may not be present. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Hypoventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with COPD, hypercapnia can be due to dead space ventilation and ventilation-perfusion mismatching from COPD or concomitant obesity hypoventilation syndrome, OSA, or neuromuscular weakness (eg, diaphragmatic paralysis). (See
         <a class="medical medical_review" href="/z/d/html/101436.html" rel="external">
          "Mechanisms, causes, and effects of hypercapnia", section on 'Mechanisms and etiologies of hypercapnia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H419451649">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of SRBD includes a variety of non-respiratory causes of sleep disturbances and daytime sleepiness. Sleep fragmentation may be due to coughing or shortness of breath and other processes that can cause SRBD that are unassociated with COPD (eg, heart failure) [
         <a href="#rid38">
          38
         </a>
         ]. Depression and anxiety are common among patients with COPD and can contribute to poor sleep quality and excessive daytime sleepiness [
         <a href="#rid56">
          56,57
         </a>
         ]. Polysomnography (PSG) is often necessary to exclude SRBD in patients with depression or anxiety. (See
         <a class="medical medical_review" href="/z/d/html/7698.html" rel="external">
          "Clinical manifestations and diagnosis of obesity hypoventilation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">
          "Sleep-disordered breathing in heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10592111">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of SRBD in patients with COPD should be individualized according to the type and severity of SRBD. Treatment options range from nocturnal oxygen in patients with isolated sleep-related hypoxemia to positive airway pressure therapy in patients with obstructive or central sleep apnea. The goals of therapy are to alleviate hypoxemia during sleep, improve sleep quality, and reduce COPD-related morbidity and possibly mortality [
         <a href="#rid38">
          38,43,58
         </a>
         ].
        </p>
        <p>
         Pharmacotherapy including anticholinergic and beta-agonist drugs and
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         are well-established treatments to improve bronchial airway properties and ventilation; thus they can also improve SRBD in COPD and poor sleep quality [
         <a href="#rid43">
          43
         </a>
         ]. The use of these treatments in COPD is discussed separately. Similarly, although lung volume reduction therapy has been shown to improve breathing mechanics and sleep, the primary indication for this intervention is not sleep-disordered breathing, and thus, it is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1430.html" rel="external">
          "Lung volume reduction surgery in COPD"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10592117">
         <span class="h2">
          Sleep-related hypoxemia
         </span>
        </p>
        <p class="headingAnchor" id="H1651864988">
         <span class="h3">
          Indications for treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe awake hypoxemia (arterial oxygen tension [PaO
         <sub>
          2
         </sub>
         ] ≤55 mmHg [7.32 kPa] or pulse oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] ≤88 percent) meet criteria for long-term oxygen therapy (LTOT) and clearly benefit from nocturnal oxygen. However, the benefit of nocturnal oxygen in patients with mild-to-moderate hypoxemia and nocturnal desaturation has not been clearly demonstrated [
         <a href="#rid59">
          59,60
         </a>
         ]. In the absence of severe daytime hypoxemia, we prescribe nocturnal oxygen for patients with nocturnal desaturation (SpO
         <sub>
          2
         </sub>
         ≤88 percent) who have associated signs or symptoms attributable to hypoxemia  (
         <a class="graphic graphic_table graphicRef76543" href="/z/d/graphic/76543.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Efficacy'
         </a>
         below.)
        </p>
        <p>
         The treatment of sleep-related hypoxemia, after exclusion of other SRBDs, is generally guided by the severity and duration of hypoxemia and associated clinical features. Medicare criteria for nocturnal oxygen supplementation include [
         <a href="#rid61">
          61
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A PaO
         <sub>
          2
         </sub>
         ≤55 mmHg (7.32 kPa) or SpO
         <sub>
          2
         </sub>
         ≤88 percent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A decrease in SpO
         <sub>
          2
         </sub>
         &gt;5 percent for at least five minutes during sleep.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated symptoms or signs reasonably attributed to hypoxemia (eg, impaired cognition, nocturnal restlessness, morning headaches, pulmonary hypertension, erythrocytosis).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of another cause of sleep-related hypoxemia (eg, OSA). If determination of nocturnal desaturation is made by overnight oximetry, concomitant OSA should be excluded by careful history and/or polysomnography. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         When indicated, supplemental oxygen is generally supplied by nasal cannula at a flow rate sufficient to maintain the SpO
         <sub>
          2
         </sub>
         in the range of 90 to 95 percent [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy"
         </a>
         .)
        </p>
        <p>
         Importantly, nocturnal oxygen therapy alone is not recommended for patients with comorbid COPD and OSA  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Obstructive sleep apnea'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H744148502">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The strength of the evidence in favor of administering supplemental oxygen to prevent long-term consequences of sleep-related hypoxemia depends on the degree of daytime hypoxemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe daytime hypoxemia
         </strong>
         – Continuous home oxygen therapy is recommended in patients with severe resting awake hypoxemia (partial pressure of arterial oxygen [PaO
         <sub>
          2
         </sub>
         ] less than 55 mmHg [8 kPa]) due to COPD because it improves survival and quality of life [
         <a href="#rid62">
          62,63
         </a>
         ]. The use of LTOT in COPD is described separately. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy", section on 'Benefits'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The exact flow rate of supplemental oxygen needed to prevent sleep-related hypoxemia may be higher than the amount needed when the patient is awake. In the Nocturnal Oxygen Therapy Trial, the oxygen flow was routinely increased by 1 L/minute during sleep [
         <a href="#rid62">
          62
         </a>
         ]. We typically obtain an overnight oximetry study to guide oxygen supplementation in patients with pulmonary hypertension or significant hyperinflation due to COPD. These patients often have significant perfusion/ventilation mismatch or a right-left shunt with severe hypoxemia that is unresponsive to supplemental oxygen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild to moderate daytime hypoxemia
         </strong>
         – While LTOT improves survival in COPD patients with severe hypoxemia, oxygen therapy during sleep has not been shown to improve survival in patients with mild to moderate daytime hypoxemia (eg, SpO
         <sub>
          2
         </sub>
         89 to 95 percent) or arterial desaturation only at night [
         <a href="#rid60">
          60,64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The hypothesis that supplemental oxygen might improve survival in patients with mild-to-moderate daytime hypoxemia (SpO
         <sub>
          2
         </sub>
         89 to 93 percent) was challenged by the long-term oxygen treatment trial (LOTT), which examined the effect of continuous supplemental oxygen in 738 such patients [
         <a href="#rid65">
          65
         </a>
         ]. In this trial, supplemental oxygen did not result in any difference in time to death or first hospitalization, rate of COPD exacerbations, or rate of COPD-related hospitalizations, nor was there a benefit in quality of life, lung function, or distance walked in six minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As the LOTT trial did not specifically assess nocturnal hypoxemia, the International Nocturnal Oxygen (INOX) trial was designed to answer whether nocturnal oxygen is of benefit in COPD patients with nocturnal hypoxemia who did not meet criteria for LTOT  (
         <a class="graphic graphic_table graphicRef76543" href="/z/d/graphic/76543.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid59">
          59
         </a>
         ]. The multicenter randomized INOX trial compared nocturnal supplemental oxygen versus air from a sham concentrator in 243 patients with an SpO
         <sub>
          2
         </sub>
         &lt;90 percent for ≥30 percent of the nocturnal home oximetry recording time [
         <a href="#rid59">
          59,60
         </a>
         ]. In the active group, oxygen was titrated to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent for &gt;90 percent of the recording time. At three years of follow-up, similar numbers of patients in the two groups met the composite outcome of death or resting SpO
         <sub>
          2
         </sub>
         ≤88 percent. Exacerbation rates, hospitalizations and quality of life were similar in the two groups. Interpretation of the trial is hampered by low recruitment (243 participants instead of planned 600) and incomplete retention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We continue to prescribe nocturnal oxygen for patients with COPD who have mild to moderate daytime hypoxemia and comorbidities such as pulmonary hypertension, right heart failure, cardiac arrhythmia, and coronary artery disease. The use of supplemental oxygen in patients with mild to moderate daytime hypoxemia is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management", section on 'Supplemental oxygen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1657345539">
         <span class="h3">
          Risk of hypoventilation with supplemental oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         In approximately 20 percent of COPD patients requiring oxygen, oxygen therapy at night can worsen hypoventilation during sleep, but this rise in CO
         <sub>
          2
         </sub>
         rarely worsens hypercapnia and acidosis in the morning [
         <a href="#rid66">
          66
         </a>
         ]. Even in patients with severe COPD (mean arterial carbon dioxide tension [PaCO
         <sub>
          2
         </sub>
         ] 53 mmHg), the administration of supplemental oxygen at night was associated with only small (&lt;6 mmHg) increases in PaCO
         <sub>
          2
         </sub>
         throughout sleep [
         <a href="#rid67">
          67
         </a>
         ]. Nevertheless, if the rise in PaCO
         <sub>
          2
         </sub>
         offsets the beneficial effect of oxygenation, institution of positive airway pressure (PAP) therapy can mitigate the worsening of hypoventilation.
        </p>
        <p class="headingAnchor" id="H1163048519">
         <span class="h2">
          Obstructive sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of OSA includes a combination of patient education, lifestyle modifications (eg, weight loss for patients who are overweight or obese, alcohol avoidance), and PAP. An overview of OSA management is provided separately along with guidance regarding the initiation and titration of PAP. (See
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7677.html" rel="external">
          "Titration of positive airway pressure therapy for adults with obstructive sleep apnea"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99556.html" rel="external">
          "Mode selection for titration of positive airway pressure in adults with obstructive sleep apnea"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H464160137">
         <span class="h3">
          Initiating positive airway pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAP is the mainstay of therapy for OSA, almost always starting with continuous positive airway pressure (CPAP). Many patients with mild-to-moderate COPD and OSA are candidates for initiation of PAP at home following diagnosis by HSAT  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Home sleep apnea test'
         </a>
         above). By contrast, patients with moderate-to-severe COPD and OSA generally require initiation and manual titration of PAP in a sleep laboratory; moderate-to-severe COPD and oxygen-dependent COPD are considered contraindications to initiating CPAP with auto-titrating devices at home. (See
         <a class="medical medical_review" href="/z/d/html/7677.html" rel="external">
          "Titration of positive airway pressure therapy for adults with obstructive sleep apnea", section on 'Modes of positive airway pressure'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiation of PAP
         </strong>
         – The initiation of PAP in patients with COPD and OSA, generally follows the protocol outlined for routine treatment of OSA and starts with CPAP at 4 cm H
         <sub>
          2
         </sub>
         O. Heated humidification is generally recommended for patients receiving CPAP. However, some patients with COPD are sensitive to changes in humidity and may report increased cough or dyspnea when the level of humidity is too high (or too low) for them. (See
         <a class="medical medical_review" href="/z/d/html/7677.html" rel="external">
          "Titration of positive airway pressure therapy for adults with obstructive sleep apnea"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – For patients with coexisting obstructive sleep apnea and COPD, use of PAP has been associated with lower mortality, morbidity, and exacerbation rates [
         <a href="#rid68">
          68,69
         </a>
         ]. In a prospective observational study, 651 COPD patients (228 with OSA and treated with CPAP, 213 with OSA but not treated with CPAP, and 210 patients without OSA) were followed for a median duration of 9.4 years [
         <a href="#rid68">
          68
         </a>
         ]. Patients with OSA not treated with CPAP had a higher mortality (relative risk 1.79, 95% CI 1.16-2.77) and were more likely to experience a severe COPD exacerbation leading to hospitalization compared with the COPD-only group. In addition, patients with OSA treated with CPAP had no increased risk for mortality or exacerbations compared with patients with COPD alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Larger observational studies have also shown an association between PAP adherence and improved outcomes in this population [
         <a href="#rid69">
          69,70
         </a>
         ]. As an example, health insurance claims data in the United States were used to identify 6810 patients with COPD and OSA who were prescribed PAP; among these, 4482 patients (66 percent) were adherent based on PAP user data [
         <a href="#rid69">
          69
         </a>
         ]. During two years of PAP therapy compared with the year before therapy in 1412 propensity score-matched patients, PAP-adherent patients showed greater reductions in emergency room visits, inpatient hospitalizations, and severe acute exacerbations compared with nonadherent patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CPAP is also effective in mitigating the excess risk of mortality in hypercapnic patients [
         <a href="#rid71">
          71
         </a>
         ] and in hypoxemic COPD patients [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1581946208">
         <span class="h3">
          CPAP failure or intolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         While CPAP is sufficient in most patients with concomitant OSA and COPD, some patients require high levels of PAP to achieve control of OSA. The American Academy of Sleep Medicine (AASM) suggests changing to bilevel positive airway pressure (BPAP) in the spontaneous mode, if residual obstructive events or snoring are observed on CPAP therapy at a pressure of ≥15 cm H
         <sub>
          2
         </sub>
         O [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         The application of PAP in patients with severe emphysema can also worsen dynamic hyperinflation and increase work of breathing, particularly at pressures exceeding 10 cm H
         <sub>
          2
         </sub>
         O [
         <a href="#rid17">
          17
         </a>
         ]. In these patients, newer PAP devices that allow reduction in expiratory pressures or even the application of bilevel PAP may help to get patients adjusted to PAP and lower the side effects.
        </p>
        <p>
         Other modalities of inspiratory pressure support (adaptive server ventilation [ASV] or auto-adapting bi-positive pressure ventilation [AVAP]) may further improve nocturnal and diurnal blood gases, although it remains unclear whether these modalities provide additional clinical benefit in these patients compared to CPAP alone [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">
          "Modes of mechanical ventilation", section on 'Adaptive support ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2271575647">
         <span class="h2">
          Central sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data regarding the consequences of central sleep-disordered breathing events in patients with COPD are lacking. Nevertheless, as for central sleep apnea (CSA) in the absence of COPD, treatment should be considered if CSA and the underlying cause (ie, heart failure) impose additional health risks to the patient [
         <a href="#rid1">
          1,75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment"
         </a>
         .)
        </p>
        <p>
         Some patients develop central apneas during the initiation of CPAP for OSA, a phenomenon known as treatment emergent CSA. The management of treatment-emergent CSA generally involves continuing CPAP, as many patients will spontaneously improve. Patients who do not improve (and do not have heart failure) can be switched to ASV; BPAP with a backup rate is a reasonable alternative. Treatment-emergent CSA is described separately. (See
         <a class="medical medical_review" href="/z/d/html/105590.html" rel="external">
          "Mode selection for positive airway pressure titration in adult patients with central sleep apnea syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14911.html" rel="external">
          "Treatment-emergent central sleep apnea"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H138312166">
         <span class="h2">
          Sleep-related hypoventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe COPD and intermittent or persistent daytime hypercapnia often experience worsening hypoventilation during sleep even in the absence of OSA.
        </p>
        <p class="headingAnchor" id="H3879027130">
         <span class="h3">
          Noninvasive ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal role for noninvasive ventilation (NIV; eg, CPAP or BPAP) in these patients is unclear and data are limited [
         <a href="#rid76">
          76
         </a>
         ]. Patients with poor sleep quality and/or daytime sleepiness may be more likely to derive benefit.
        </p>
        <p>
         Nocturnal NIV has been used in combination with supplemental oxygen in patients with daytime hypercapnia and may improve survival, but not necessarily quality of life [
         <a href="#rid76">
          76
         </a>
         ]. Nocturnal NIV with supplemental oxygen improved sleep quality and daytime blood gases better than oxygen alone in some studies [
         <a href="#rid77">
          77,78
         </a>
         ], but not in others [
         <a href="#rid79">
          79
         </a>
         ]. The benefits on sleep and daytime blood gases have been attributed to improvements in breathing mechanics such as reductions in micro-atelectasis with positive pressure, prevention of collapse in the intrapulmonary airways, and reduction in work of breathing all of which contribute to resting of chronically fatigued respiratory muscles [
         <a href="#rid43">
          43
         </a>
         ]. The rationale for nocturnal NIV in COPD, its implementation, and effects on survival and quality of life in patients with COPD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1453.html" rel="external">
          "Nocturnal ventilatory support in COPD"
         </a>
         .)
        </p>
        <p>
         For patients with sleep-related hypoventilation due to COPD, PAP is typically initiated in a sleep laboratory, if it has not already been titrated during a hospitalization. The details of initiation of nocturnal NIV in hypercapnic patients with COPD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1453.html" rel="external">
          "Nocturnal ventilatory support in COPD", section on 'Practical aspects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H578796210">
         <span class="h3">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory stimulants such as progestational agents,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9832" href="/z/d/drug information/9832.html" rel="external">
          protriptyline
         </a>
         were once used to treat hypercapnia, but the benefits were modest and not maintained. They are rarely utilized for this indication. (See
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment", section on 'Pharmacologic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5113.html" rel="external">
          "Disorders of ventilatory control", section on 'Drugs affecting ventilatory drive'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2361767508">
         <span class="h2">
          Other sleep disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of restless leg syndrome and insomnia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/88241.html" rel="external">
          "Management of restless legs syndrome and periodic limb movement disorder in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">
          "Overview of the treatment of insomnia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1396549648">
         <span class="h1">
          FUTURE DIRECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing research is aimed at determining whether nocturnal oxygen therapy is beneficial in mild hypoxemia (see
         <a class="local">
          'Sleep-related hypoxemia'
         </a>
         above), whether adaptive server ventilation (ASV) or auto-adapting bi-positive pressure ventilation (AVAP) have a role in the treatment for central sleep apnea (CSA), and whether more comfortable and effective interfaces and modes for treating SRBD in patients with COPD will improve sleep quality and adherence.
        </p>
        <p>
         As an example, nasal high flow therapy with oxygen or room air is being studied for a potential role in SRBD. Positive airway pressure (continuous positive airway pressure [CPAP], bilevel positive airway pressure [BPAP]), noninvasive ventilation (NIV), and long-term oxygen therapy are the mainstream treatments for sleep-disordered breathing in COPD, but adherence rates are low [
         <a href="#rid80">
          80-82
         </a>
         ]. Preliminary data suggest that nasal high flow of warm and humidified air (NHF) may represent an alternative means to improve sleep-disordered breathing in these patients.
        </p>
        <p>
         NHF of oxygen or room air through an open nasal cannula was first introduced to improve oxygenation in infants and children with hypoxic respiratory failure [
         <a href="#rid83">
          83
         </a>
         ]. It has subsequently been extended to adult pulmonary care [
         <a href="#rid84">
          84-86
         </a>
         ]. Moreover, several studies demonstrate that it may improve arterial blood gases and exacerbation rate in COPD patients with hypercapnic respiratory failure [
         <a href="#rid87">
          87,88
         </a>
         ]. The mechanisms have been attributed to reductions in dead space ventilation [
         <a href="#rid89">
          89
         </a>
         ], slight increases in positive expiratory pressure [
         <a href="#rid90">
          90
         </a>
         ], and reductions in work of breathing [
         <a href="#rid89">
          89
         </a>
         ], compared with supplemental oxygen alone [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         Although several nasal high flow medical devices exist for use in various hospital settings using pressurized air outlets (eg, TNI Soft Flow, Optiflow, Precision Flow) there are only a few devices that provide adequate comfort and minimal noise required for use during sleep. Whether nocturnal use of NHF air can prevent nocturnal hypercapnia and improve daytime outcomes similar to CPAP or long-term oxygen therapy is being examined in several clinical trials [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2374725138">
         <span class="h1">
          PROGNOSTIC IMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         SRBD may adversely affect quality of life, morbidity, and mortality in patients with COPD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related hypoxemia
         </strong>
         – Several lines of evidence suggest that sleep-related hypoxemia may increase morbidity and mortality in COPD. First, in the Nocturnal Oxygen Treatment Trial [
         <a href="#rid14">
          14,62
         </a>
         ], a post hoc analysis revealed increased mortality in patients with nocturnal hypoxemia. Second, sleep-related oxygen desaturation has been associated with worsening pulmonary hypertension and cor pulmonale [
         <a href="#rid94">
          94,95
         </a>
         ]. Third, sleep-related hypoxemia is associated with neurocognitive dysfunction [
         <a href="#rid96">
          96,97
         </a>
         ], which can improve with treatment for sleep-disordered breathing [
         <a href="#rid98">
          98
         </a>
         ]. Nevertheless, studies examining the effects of nocturnal oxygen administration on outcomes in COPD have been inconclusive due to small sample sizes and high attrition rates [
         <a href="#rid14">
          14,18,99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstructive sleep apnea
         </strong>
         – Several large studies now show that the coexistence of obstructive sleep apnea (OSA) is a negative prognostic predictor for both cardiovascular disease and mortality in COPD patients [
         <a href="#rid68">
          68,100,101
         </a>
         ]. In a retrospective case control study consisting of 10,981 males with OSA, comorbid COPD was associated with a seven-fold increased risk for all-cause mortality [
         <a href="#rid100">
          100
         </a>
         ]. Decreased survival has been attributed to a greater frequency of exacerbations, more severe hypoxemia and hypercapnia, pulmonary hypertension, and cor pulmonale with potentially lethal arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – While pulmonary hypertension (PH) is not common in patients with even severe OSA, the risk for having pulmonary arterial hypertension with OSA is increased in patients with coexisting COPD, chronic hypoventilation, and obesity [
         <a href="#rid64">
          64
         </a>
         ]. The prevalence of pulmonary hypertension in patients with COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 to 3 is approximately 25 percent (22 to 27 percent) and increases to 33 to 53 percent in patients with GOLD stage 4 COPD [
         <a href="#rid102">
          102,103
         </a>
         ]. The combination of OSA and COPD increased right ventricular remodeling compared to COPD alone and may explain the increased mortality compared to COPD or OSA alone. Nevertheless, compared with daytime hypoxia, hypercapnia and reduced forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), indices that reflect OSA severity (such as apnea hypopnea index [AHI] or oxygen desaturation index), play a minor role for developing pulmonary hypertension and right heart failure [
         <a href="#rid43">
          43,58
         </a>
         ]. Moreover, while daytime hypoxemia is the strongest predictor for the development of PH, there is no evidence that nocturnal hypoxia alone increases the risk for PH.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1302187472">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113310.html" rel="external">
          "Society guideline links: Sleep-related breathing disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H49335517">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Chronic obstructive pulmonary disease (COPD) is associated with a spectrum of sleep-related breathing disorders (SRBD; formerly called sleep disordered breathing) that include sleep-related hypoxemia, obstructive sleep apnea (OSA), central sleep apnea, respiratory effort-related arousals, sleep-related hypoventilation, restless leg syndrome, and insomnia. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contributing factors
         </strong>
         – The majority of patients with COPD have at least one comorbid condition and more than half have at least four coexisting conditions (eg, obesity, heart failure, smoking, opioid use) that are associated with a higher prevalence of SRBDs. (See
         <a class="local">
          'Contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The symptoms and signs of SRBD in patients with COPD are essentially the same as for those without COPD (eg, snoring, insomnia, awakening with gasping or choking, morning headaches, daytime sleepiness or fatigue, and poor concentration or memory impairment). However, patients may be asymptomatic or may have symptoms that overlap with the features of COPD itself and thus not report them. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – The diagnosis of SRBD in patients with COPD requires a high index of suspicion and formal sleep testing with polysomnography. Indications include symptoms of SRBD, obesity (body mass index [BMI] &gt;35), neck circumference &gt;43 cm (17 inches) in males or &gt;41 cm (16 inches) in females, pulse oxygen saturation [SpO
         <sub>
          2
         </sub>
         ] &lt;93 percent, daytime hypercapnia, pulmonary hypertension, or cor pulmonale. (See
         <a class="local">
          'When should SRBD be suspected in COPD?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a high likelihood of OSA and without baseline hypercapnia, it may be practical to obtain a split-night study due to issues with accessibility; otherwise a full night polysomnogram is preferred. When possible, continuous monitoring of carbon dioxide via an end-tidal (etCO
         <sub>
          2
         </sub>
         ) or transcutaneous (tcCO
         <sub>
          2
         </sub>
         ) system, is helpful, particularly in patients with daytime hypercapnia or daytime hypoxemia  (
         <a class="graphic graphic_algorithm graphicRef114079" href="/z/d/graphic/114079.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'In-laboratory polysomnography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diagnostic criteria for the various SRBD have been established by the American Academy of Sleep Medicine. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Continuous supplemental oxygen is indicated for patients with severe awake hypoxemia (ie, PaO
         <sub>
          2
         </sub>
         ≤55 mmHg [7.32 kPa] or SpO
         <sub>
          2
         </sub>
         ≤88 percent). A clinical benefit to nocturnal oxygen has not been demonstrated for most patients with COPD and sleep-related desaturation, but without severe daytime hypoxemia or other SRBD. For patients with symptoms or signs reasonably attributable to nocturnal desaturation (eg, impaired cognition, nocturnal restlessness, morning headaches, pulmonary hypertension, erythrocytosis), a trial of nocturnal oxygen supplementation may be reasonable. Indications for oxygen supplementation in patients who have mild-to-moderate hypoxemia and certain comorbidities are listed in the table  (
         <a class="graphic graphic_table graphicRef76543" href="/z/d/graphic/76543.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Sleep-related hypoxemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management", section on 'Supplemental oxygen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment of OSA in patients with COPD includes a combination of patient education, lifestyle modifications, and positive airway pressure (PAP). Initiation and titration of PAP should be performed manually in a sleep laboratory. (See
         <a class="local">
          'Obstructive sleep apnea'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with hypercapnia due to severe COPD, nocturnal noninvasive ventilation may improve survival but not necessarily quality of life. The role of nocturnal NIV in patients with severe COPD is discussed separately. (See
         <a class="local">
          'Noninvasive ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10592135">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Peter Gay, MD, and Hartmut Schneider, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med 2015; 11:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 2009; 64:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanfulla F, Cascone L, Taurino AE. Sleep disordered breathing in patients with chronic obstructive pulmonary disease. Minerva Med 2004; 95:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbano F, Mohsenin V. Chronic obstructive pulmonary disease and sleep: the interaction. Panminerva Med 2006; 48:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011; 20:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavalcante AG, de Bruin PF, de Bruin VM, et al. Restless legs syndrome, sleep impairment, and fatigue in chronic obstructive pulmonary disease. Sleep Med 2012; 13:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslin E, van der Schans C, Breukink S, et al. Perception of fatigue and quality of life in patients with COPD. Chest 1998; 114:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan VS, Curtis JR, Tu SP, et al. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen R, Tian JW, Zhou LQ, et al. The relationship between sleep quality and functional exercise capacity in COPD. Clin Respir J 2016; 10:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geiger-Brown J, Lindberg S, Krachman S, et al. Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du D, Zhang G, Xu D, et al. Prevalence and clinical characteristics of sleep disorders in chronic obstructive pulmonary disease: A systematic review and meta-analysis. Sleep Med 2023; 112:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 2015; 3:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med 1985; 6:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donoghue FJ, Catcheside PG, Ellis EE, et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. Eur Respir J 2003; 21:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleetham J, West P, Mezon B, et al. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982; 126:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med 2012; 13:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon JS, Wolfe LF, Lu BS, Kalhan R. Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea. COPD 2009; 6:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skatrud JB, Dempsey JA, Iber C, Berssenbrugge A. Correction of CO2 retention during sleep in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1981; 124:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donoghue FJ, Catcheside PG, Eckert DJ, McEvoy RD. Changes in respiration in NREM sleep in hypercapnic chronic obstructive pulmonary disease. J Physiol 2004; 559:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 2005; 32:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas NJ, White DP, Weil JV, et al. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis 1982; 126:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol Respir Environ Exerc Physiol 1978; 44:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mezzanotte WS, Tangel DJ, White DP. Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls. Am J Respir Crit Care Med 1996; 153:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson PL, Edwards N, Burgess KR, Sullivan CE. Detection of increased upper airway resistance during overnight polysomnography. Sleep 2005; 28:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol (1985) 2008; 105:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MOTLEY HL. THE EFFECTS OF SLOW DEEP BREATHING ON THE BLOOD GAS EXCHANGE IN EMPHYSEMA. Am Rev Respir Dis 1963; 88:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingram RH Jr, Schilder DP. Effect of pursed lips expiration on the pulmonary pressure-flow relationship in obstructive lung disease. Am Rev Respir Dis 1967; 96:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoman RL, Stoker GL, Ross JC. The efficacy of pursed-lips breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1966; 93:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catterall JR, Calverley PM, MacNee W, et al. Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema. J Appl Physiol (1985) 1985; 59:1698.
          </a>
         </li>
         <li class="breakAll">
          Gothe B, Bruce E, Goldman MD. Influence of Sleep State on Respiratory Muscle Function. In: Sleep and Breathing, Saunders NA, Sullivan CE (Eds), Marcel Dekker, Inc, New York 1984. p.241.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biselli P, Grossman PR, Kirkness JP, et al. The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep. J Appl Physiol (1985) 2015; 119:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider H, Krishnan V, Pichard LE, et al. Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation. Eur Respir J 2009; 33:1068.
          </a>
         </li>
         <li class="breakAll">
          Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD). NCT01764165. https://clinicaltrials.gov/ct2/show/NCT01764165?term=copd+and+sleep&amp;rank=10 (Accessed on November 13, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. Ann Am Thorac Soc 2014; 11:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. Respir Investig 2015; 53:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetter DW, Young TB, Bidwell TR, et al. Smoking as a risk factor for sleep-disordered breathing. Arch Intern Med 1994; 154:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaehne A, Unbehaun T, Feige B, et al. Sleep changes in smokers before, during and 3 months after nicotine withdrawal. Addict Biol 2015; 20:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Underner M, Paquereau J, Meurice JC. [Cigarette smoking and sleep disturbance]. Rev Mal Respir 2006; 23:6S67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambam JR, Chen LH, Hyman SA. Effect of short-term smoking halt on carboxyhemoglobin levels and P50 values. Anesth Analg 1986; 65:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev 2013; 22:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price D, Small M, Milligan G, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis 2013; 8:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faria AC, da Costa CH, Rufino R. Sleep Apnea Clinical Score, Berlin Questionnaire, or Epworth Sleepiness Scale: which is the best obstructive sleep apnea predictor in patients with COPD? Int J Gen Med 2015; 8:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alchakaki A, Riehani A, Shikh-Hamdon M, et al. Expiratory Snoring Predicts Obstructive Pulmonary Disease in Patients with Sleep-disordered Breathing. Ann Am Thorac Soc 2016; 13:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobert DG, Gay PC. New directions for pulse oximetry in sleep disorders. Mayo Clin Proc 1995; 70:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacasse Y, Sériès F, Vujovic-Zotovic N, et al. Evaluating nocturnal oxygen desaturation in COPD--revised. Respir Med 2011; 105:1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis CA, Eaton TE, Fergusson W, et al. Home overnight pulse oximetry in patients with COPD: more than one recording may be needed. Chest 2003; 123:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira MG, Nery LE, Santos-Silva R, et al. Is portable monitoring accurate in the diagnosis of obstructive sleep apnea syndrome in chronic pulmonary obstructive disease? Sleep Med 2012; 13:1033.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </li>
         <li class="breakAll">
          Troester MM, Quan SF, Berry RB, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 3, American Academy of Sleep Medicine, 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med 2012; 12:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayers AG, Baldwin DS. The relationship between sleep disturbance and depression. Int J Psychiatry Clin Pract 2006; 10:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee R, McNicholas WT. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2011; 17:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacasse Y, Bernard S, Sériès F, et al. Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulm Med 2017; 17:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacasse Y, Sériès F, Corbeil F, et al. Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. N Engl J Med 2020; 383:1129.
          </a>
         </li>
         <li class="breakAll">
          Centers for Medicare and Medicaid Services. Home Oxygen Therapy. Department of Health and Human Services, 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The nocturnal oxygen therapy trial--NOTT). Chest 1980; 78:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn WF, Nelson SB, Hubmayr RD. Oxygen-induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 1984; 310:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterling KL, Pépin JL, Linde-Zwirble W, et al. Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2022; 206:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanchina ML, Welicky LM, Donat W, et al. Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med 2013; 9:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaoude P, Kufel T, El-Solh AA. Survival benefit of CPAP favors hypercapnic patients with the overlap syndrome. Lung 2014; 192:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushida CA, Littner MR, Hirshkowitz M, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 2006; 29:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crimi C, Noto A, Princi P, et al. Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices. COPD 2016; 13:483.
          </a>
         </li>
         <li class="breakAll">
          Berry RB, Brooks R, Gamaldo CE, et al. The AASM Manual for Scoring Sleep and Associated Events: Rules, Terminology and Technical Specifications. Darien: AASM; 2012.
         </li>
         <li class="breakAll">
          Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; :CD004104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Struik FM, Lacasse Y, Goldstein R, et al. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; :CD002878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windisch W, Storre JH, Köhnlein T. Nocturnal non-invasive positive pressure ventilation for COPD. Expert Rev Respir Med 2015; 9:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotecha SJ, Adappa R, Gupta N, et al. Safety and Efficacy of High-Flow Nasal Cannula Therapy in Preterm Infants: A Meta-analysis. Pediatrics 2015; 136:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corley A, Caruana LR, Barnett AG, et al. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth 2011; 107:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care 2014; 59:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372:2185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rea H, McAuley S, Jayaram L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med 2010; 104:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilius G, Franke KJ, Domanski U, et al. Effects of nasal insufflation on arterial gas exchange and breathing pattern in patients with chronic obstructive pulmonary disease and hypercapnic respiratory failure. Adv Exp Med Biol 2013; 755:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mündel T, Feng S, Tatkov S, Schneider H. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. J Appl Physiol (1985) 2013; 114:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGinley BM, Patil SP, Kirkness JP, et al. A nasal cannula can be used to treat obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biselli PJ, Kirkness JP, Grote L, et al. Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. J Appl Physiol (1985) 2017; 122:82.
          </a>
         </li>
         <li class="breakAll">
          Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD), NCT01764165 . https://clinicaltrials.gov/ct2/show/NCT01764165?term=NCT01764165&amp;rank=1 (Accessed on February 16, 2016).
         </li>
         <li class="breakAll">
          High-flow Nasal Cannula Therapy for Stable Chronic Obstructive Pulmonary Disease (COPD), NCT02545855. https://clinicaltrials.gov/ct2/show/NCT02545855?term=NCT02545855&amp;rank=1 (Accessed on February 16, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coccagna G, Lugaresi E. Arterial blood gases and pulmonary and systemic arterial pressure during sleep in chronic obstructive pulmonary disease. Sleep 1978; 1:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Punjabi NM, Bandeen-Roche K, Marx JJ, et al. The association between daytime sleepiness and sleep-disordered breathing in NREM and REM sleep. Sleep 2002; 25:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engleman HM, Kingshott RN, Martin SE, Douglas NJ. Cognitive function in the sleep apnea/hypopnea syndrome (SAHS). Sleep 2000; 23 Suppl 4:S102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas NJ, Engleman HM. Effects of CPAP on vigilance and related functions in patients with the sleep apnea/hypopnea syndrome. Sleep 2000; 23 Suppl 4:S147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992; 145:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case-control study. J Sleep Res 2007; 16:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donovan LM, Feemster LC, Udris EM, et al. Poor Outcomes Among Patients With Chronic Obstructive Pulmonary Disease With Higher Risk for Undiagnosed Obstructive Sleep Apnea in the LOTT Cohort. J Clin Sleep Med 2019; 15:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilde JM, Skjørten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J 2013; 41:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilde JM, Skjørten I, Grøtta OJ, et al. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol 2013; 62:1103.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7680 Version 42.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25700872" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12502472" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18390630" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15334044" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sleep disordered breathing in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215794" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Chronic obstructive pulmonary disease and sleep: the interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881146" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Night-time symptoms: a forgotten dimension of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22727926" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Restless legs syndrome, sleep impairment, and fatigue in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9792561" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Perception of fatigue and quality of life in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204865" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12171813" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25515647" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The relationship between sleep quality and functional exercise capacity in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25759571" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37950939" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence and clinical characteristics of sleep disorders in chronic obstructive pulmonary disease: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10596681" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25682233" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2935359" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sleep in chronic obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12797491" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7125332" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429651" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19938967" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7025715" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Correction of CO2 retention during sleep in patients with chronic obstructive pulmonary diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15235077" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Changes in respiration in NREM sleep in hypercapnic chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837726" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7149440" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hypercapnic ventilatory response in sleeping adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/670014" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pathogenesis of upper airway occlusion during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8665050" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15700724" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Detection of increased upper airway resistance during overnight polysomnography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18678624" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The major limitation to exercise performance in COPD is dynamic hyperinflation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14068433" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : THE EFFECTS OF SLOW DEEP BREATHING ON THE BLOOD GAS EXCHANGE IN EMPHYSEMA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6039092" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of pursed lips expiration on the pulmonary pressure-flow relationship in obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5901381" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The efficacy of pursed-lips breathing in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4077777" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4077777" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26048975" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129290" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129290" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24625243" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26521102" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Comorbidity in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7944843" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Smoking as a risk factor for sleep-disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24797355" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sleep changes in smokers before, during and 3 months after nicotine withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16820750" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : [Cigarette smoking and sleep disturbance].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3767017" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effect of short-term smoking halt on carboxyhemoglobin levels and P50 values.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23997063" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sleep disorders in COPD: the forgotten dimension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24348032" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Impact of night-time symptoms in COPD: a real-world study in five European countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16171294" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Practice parameters for the indications for polysomnography and related procedures: an update for 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26345497" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Sleep Apnea Clinical Score, Berlin Questionnaire, or Epworth Sleepiness Scale: which is the best obstructive sleep apnea predictor in patients with COPD?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15219010" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26630563" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Expiratory Snoring Predicts Obstructive Pulmonary Disease in Patients with Sleep-disordered Breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7776722" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : New directions for pulse oximetry in sleep disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21561753" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Evaluating nocturnal oxygen desaturation in COPD--revised.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12684303" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Home overnight pulse oximetry in patients with COPD: more than one recording may be needed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28162150" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22841038" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Is portable monitoring accurate in the diagnosis of obstructive sleep apnea syndrome in chronic pulmonary obstructive disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22841038" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Is portable monitoring accurate in the diagnosis of obstructive sleep apnea syndrome in chronic pulmonary obstructive disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22841038" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Is portable monitoring accurate in the diagnosis of obstructive sleep apnea syndrome in chronic pulmonary obstructive disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22958576" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24926763" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The relationship between sleep disturbance and depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21169840" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Obstructive sleep apnea in chronic obstructive pulmonary disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069009" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32937046" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32937046" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6776858" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6110912" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7418460" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The nocturnal oxygen therapy trial--NOTT)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27783918" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1909846" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Oxygen-induced hypercarbia in obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6420700" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20378728" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436176" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946706" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24452812" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Survival benefit of CPAP favors hypercapnic patients with the overlap syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19574323" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16553024" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744042" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744042" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744042" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7633704" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15266518" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23766138" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12358325" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19213769" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896807" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Nocturnal non-invasive positive pressure ventilation for COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26283781" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Safety and Efficacy of High-Flow Nasal Cannula Therapy in Preterm Infants: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908497" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24046462" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25981908" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20144858" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The clinical utility of long-term humidification therapy in chronic airway disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22826046" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Effects of nasal insufflation on arterial gas exchange and breathing pattern in patients with chronic obstructive pulmonary disease and hypercapnic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23412897" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Mechanisms of nasal high flow on ventilation during wakefulness and sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17363769" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A nasal cannula can be used to treat obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27815367" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27815367" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27815367" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/227027" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Arterial blood gases and pulmonary and systemic arterial pressure during sleep in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4003933" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12003161" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The association between daytime sleepiness and sleep-disordered breathing in NREM and REM sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893080" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cognitive function in the sleep apnea/hypopnea syndrome (SAHS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893090" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Effects of CPAP on vigilance and related functions in patients with the sleep apnea/hypopnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1586049" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17309772" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Mortality risk factors in sleep apnoea: a matched case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30621828" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Poor Outcomes Among Patients With Chronic Obstructive Pulmonary Disease With Higher Risk for Undiagnosed Obstructive Sleep Apnea in the LOTT Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22903957" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Haemodynamic responses to exercise in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23831444" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
